Skip to Content

Are you based in North America? If yes, switch to our North American website →

D13S319 Plus Deletion

Applications
haematology
Catalogue Numbers
LPH 068 (10 tests)
LPH 068-S (5 tests)

Chromosome 13q abnormalities occur in 16-40% of multiple myeloma cases and are associated with poor prognosis1,2.

A case study has shown that in 90% of patients, the 13q14 region was affected and 68% also showed involvement of the 13q21 region – the critical region in all but 8 patients was narrowed down to 13q143. Deletions affecting 13q14 are also the most frequent structural genetic abnormalities in B-cell Chronic Lymphocytic Leukaemia (B-CLL)4. This region is found to be heterozygously deleted in 30-60% and homozygously deleted in 10-20% of CLL patients5. Recently though, the survival rate has been shown to be similar for the two groups6.

Two non-coding RNA genes, DLEU1 and DLEU2, and the genetic marker D13S319, span the pathogenic critical region of 13q147. DLEU1 is considered to be the most likely CLL-associated candidate tumour suppressor gene within the 13q14 region8. Subsequently, D13S319, located between the RB1 gene and D13S25 and within the DLEU1 locus, was found to be deleted in 44% of CLL cases9. It has also been postulated that a gene telomeric to the D13S319 region, encompassing D13S25, may be important in cases with hemizygous deletions and that this gene is a putative tumour suppressor gene10.

The quality of the products we have received from Cytocell have been excellent. The FISH probes they provide to us give intense, strong signals and are a pleasure to count. What has really stood out however has been the level of support and assistance provided by Cytocell’s application specialists. The team worked very closely alongside our own during the adoption of this product and spent many hours with us perfecting the technique, going above and beyond what I would expect during the transition period. Source BioScience absolutely demand high quality products and service to be able to deliver our results with confidence, and that is what we have received from Cytocell. Neil Ryan, Laboratory Operations Manager at Source BioScience

References

1. Bullrich F et al., Cancer Res 2001;61:6640-8

2. Zojer et al., Blood 2000;95(6):1925-1930

3. Shaughnessy J et al., Blood 2000;96:1505-11

4. Juliusson G et al., N Eng J Med 1990;323:720-4

5. Hammarsund M et al., FEBS Letters 2004;556:75-80

6. Van Dyke DL et al., Br J Haematology 2009;148:544-50

7. Liu Y et al., Oncogene 1997;15:2463-73

8. Wolf S et al., Hum Mol Genet 2001;10:1275-85

9. Liu Y et al., Blood 1995;86:1911-5

10. Bullrich F et al., Blood 1996;88(8):3109-15

Microscope Images

D13S319 Plus Deletion magnified
Area of Interest*
CLL, MM

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.